AU2005293802A1 - Use of organic compounds - Google Patents

Use of organic compounds Download PDF

Info

Publication number
AU2005293802A1
AU2005293802A1 AU2005293802A AU2005293802A AU2005293802A1 AU 2005293802 A1 AU2005293802 A1 AU 2005293802A1 AU 2005293802 A AU2005293802 A AU 2005293802A AU 2005293802 A AU2005293802 A AU 2005293802A AU 2005293802 A1 AU2005293802 A1 AU 2005293802A1
Authority
AU
Australia
Prior art keywords
calcitonin
bone
treatment
salmon calcitonin
severe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005293802A
Other languages
English (en)
Inventor
Moise Azria
Claus Christiansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Nordic Bioscience AS
Original Assignee
Novartis AG
Nordic Bioscience AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33443790&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2005293802(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG, Nordic Bioscience AS filed Critical Novartis AG
Publication of AU2005293802A1 publication Critical patent/AU2005293802A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2005293802A 2004-10-12 2005-10-10 Use of organic compounds Abandoned AU2005293802A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0422644.5A GB0422644D0 (en) 2004-10-12 2004-10-12 Organic compounds
GB0422644.5 2004-10-12
PCT/EP2005/010892 WO2006040114A1 (en) 2004-10-12 2005-10-10 Use of organic compounds

Publications (1)

Publication Number Publication Date
AU2005293802A1 true AU2005293802A1 (en) 2006-04-20

Family

ID=33443790

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005293802A Abandoned AU2005293802A1 (en) 2004-10-12 2005-10-10 Use of organic compounds

Country Status (13)

Country Link
US (1) US20090048157A1 (https=)
EP (1) EP1802328A1 (https=)
JP (1) JP2008515947A (https=)
KR (1) KR20070061864A (https=)
CN (1) CN101035556A (https=)
AU (1) AU2005293802A1 (https=)
BR (1) BRPI0516872A (https=)
CA (1) CA2580766A1 (https=)
GB (1) GB0422644D0 (https=)
MX (1) MX2007004259A (https=)
RU (1) RU2007117492A (https=)
TW (1) TW200628168A (https=)
WO (1) WO2006040114A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006318815B2 (en) * 2005-11-17 2010-08-19 Novartis Ag Pharmaceutical composition

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102292346B (zh) 2009-01-22 2015-12-02 关键生物科学有限公司 肥胖的治疗
EP2773365B1 (en) * 2011-11-02 2016-07-20 KeyBioscience AG Peptide analogs for treating diseases and disorders
BR112014010701A2 (pt) * 2011-11-02 2020-06-23 Keybioscience Ag Uso de um peptídeo
US9533022B2 (en) 2011-11-02 2017-01-03 KeyBioscience A/S Peptide analogs for treating diseases and disorders
CN107345965A (zh) * 2016-05-04 2017-11-14 广州优迪生物科技有限公司 一种同时检测N-MID和β-CTX的双标记时间分辨荧光免疫分析方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
GB9108634D0 (en) * 1991-04-23 1991-06-12 Ciba Geigy Pharmaceutical compositions
DE726075T1 (de) * 1995-02-08 1996-12-12 Therapicon Srl Nicht-inorganische pharmazeutische salzige Lösungen zur endonasale Verabreichung
IT1282374B1 (it) * 1996-01-31 1998-03-20 Therapicon Srl Composizioni farmaceutiche parenterali a base di calcitonine sintetiche a ph controllato con basso indice di dolorosita'
EP1175390B1 (en) * 1999-04-05 2005-02-02 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
US20040110170A1 (en) * 2002-05-18 2004-06-10 The Regents Of The University Of California Cloning and characterization of calcitonin gene related peptide receptors
TW200411053A (en) * 2002-12-30 2004-07-01 Ind Tech Res Inst Nucleic acid encoding recombinant salmon calcitionin, expression vector thereof, and method for producing recombinant salmon calcitonin therewith

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006318815B2 (en) * 2005-11-17 2010-08-19 Novartis Ag Pharmaceutical composition

Also Published As

Publication number Publication date
RU2007117492A (ru) 2008-11-20
WO2006040114A1 (en) 2006-04-20
BRPI0516872A (pt) 2008-09-23
KR20070061864A (ko) 2007-06-14
JP2008515947A (ja) 2008-05-15
US20090048157A1 (en) 2009-02-19
MX2007004259A (es) 2007-05-11
EP1802328A1 (en) 2007-07-04
CN101035556A (zh) 2007-09-12
GB0422644D0 (en) 2004-11-10
TW200628168A (en) 2006-08-16
CA2580766A1 (en) 2006-04-20

Similar Documents

Publication Publication Date Title
EP1937244B1 (en) Treatment of cancer with specific rxr agonists
ES2630012T3 (es) Formulaciones virales liofilizadas
JP2000511188A (ja) シス―ドコサヘキサエン酸とｔａｘ―その他との共有複合体を含有する製剤
EP2134341B1 (en) Method of treating cell proliferative disorders using growth hormone secretagogues
EP3912634B1 (en) Cancer stem cell targeted cancer vaccines
US20090048157A1 (en) Use of organic compounds
US7816323B2 (en) Methods of using corticotropin-releasing factor for the use of the treatment of cancer
US20120183536A1 (en) Methods of using corticotropin-releasing factor for the treatment of cancer
WO2004065572A2 (en) Proteic binding partners of tctp and methods of modulating tumor reversion or cell apoptosis
EP2504703B1 (en) Immunomodulatory compounds for the restoration of vitamin d sensitivity in vitamin d resistant tumor cells
US20070135448A1 (en) Use of cathepsin k inhibitors for treating of severe bone loss diseases
KR20110021820A (ko) 암 치료를 위한 부신 피질 자극 호르몬 방출 인자의 사용 방법
US20240216465A1 (en) Method for treating refractory brain tumor
WO2007143096A2 (en) Compounds for treating cancers
HK40059978B (en) Cancer stem cell targeted cancer vaccines
HK40059978A (en) Cancer stem cell targeted cancer vaccines
WO2006063762A1 (en) Dipeptide nitriles
WO1999004817A1 (en) Chemotherapy synergistic agent
KR20090061356A (ko) 제니스테인을 포함하는 유방암 치료 및 예방용 조성물

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted